Want to see JP:4544 full AI Analyst Report?
HUGroup Holdings (4544) Stock Price & Analysis
4544 Stock Chart & Stats
- Day’s Range
- JPY 3,829.00 - JPY 3,936.00
- 52-Week Range
- JPY 2,944.50 - JPY 3,954.00
- Previous Close
- JPY 3,822.00
- Volume
- 376.70K
- Average Volume (3M)
- 173.67K
- Market Cap
- JPY 224.82B
- Enterprise Value
- JPY 198.15B
- Total Cash (Recent Filing)
- JPY 44.51B
- Total Debt (Recent Filing)
- JPY 60.27B
- Price to Earnings (P/E)
- 22.8
- Beta
- 0.29
- Next Earnings
- Nov 11, 2026 (Est.)
- EPS Estimate
- 23.69
- Next Dividend Ex-Date
- Mar 30, 2027
- Dividend Yield
- 3.18%
Bulls Say, Bears Say
Bulls Say
Revenue And Earnings Recovery
The strong TTM revenue rebound shows materially improved demand for the company’s diagnostic services, while the return to positive earnings indicates operating recovery. If sustained, this combination can rebuild earnings capacity and provide a stronger base for performance over the next several quarters.
Free Cash Flow Quality
Free cash flow that broadly tracks net income provides evidence that reported profits are generating usable cash rather than remaining primarily accounting-based. This supports internal funding for operations, investment, and shareholder distributions, strengthening financial resilience during the recovery.
Improved Leverage
Lower debt relative to equity improves the company’s financial flexibility and reduces the burden that leverage places on future cash flows. A healthier capital structure gives HUGroup more capacity to manage earnings volatility and fund its diagnostic-services business without relying as heavily on additional borrowing.
Bears Say
Subdued Profit Margins
Although profitability has recovered, the much lower TTM net margin shows that HUGroup has not regained its earlier earnings efficiency. The gap leaves less profit from each unit of revenue and means the business remains more exposed to operating volatility until margins demonstrate a durable return toward historical levels.
Weak Cash Conversion Relative To Revenue
Strong free cash flow is a positive, but operating cash flow remains modest relative to revenue, indicating that cash conversion is not yet especially robust. If this pattern fluctuates, it could limit the cash available to support investment, distributions, or balance-sheet improvement despite the return to accounting profitability.
Returns Remain Below Historical Peaks
The company is generating positive returns again, but ROE remains well below its prior peak, showing that the larger equity base is not yet producing comparable shareholder profitability. This limits the quality of the recovery and suggests earnings power has not fully normalized across the business.
HUGroup Holdings News
4544 FAQ
What was HUGroup Holdings’s price range in the past 12 months?
What is HUGroup Holdings’s market cap?
When is HUGroup Holdings’s upcoming earnings report date?
How were HUGroup Holdings’s earnings last quarter?
Is HUGroup Holdings overvalued?
Does HUGroup Holdings pay dividends?
What is HUGroup Holdings’s EPS estimate?
How many shares outstanding does HUGroup Holdings have?
What happened to HUGroup Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of HUGroup Holdings?
What is the TipRanks Smart Score and how is it calculated?
Company Description
HUGroup Holdings
Established in 1950 and headquartered in Tokyo, Japan, H.U. Group Holdings, Inc. (formerly Miraca Holdings Inc. until its rebranding in July 2020) provides an extensive array of laboratory testing products and services through its subsidiaries across Japan. The company delivers diagnostic testing and associated services to medical facilities, supports self-medication initiatives, and conducts testing for food, environmental samples, and cosmetic products. Additionally, it offers testing solutions tailored for corporate health insurance programs. The group is deeply involved in the research, development, manufacturing, and commercialization of in vitro diagnostic devices. Its product lineup features the LUMIPULSE, an automated chemiluminescent enzyme immunoassay system that supplies reagents for the detection of infectious diseases, various cancers, and lifestyle-related conditions to medical institutions and diagnostic centers. H.U. Group also produces the ESPRINE series of rapid diagnostic kits for ailments such as influenza, hepatitis B, and the novel coronavirus, alongside supplying essential ingredients for test drugs. Beyond diagnostics, the company offers crucial support services for hospital administration, including assistance during surgical and endoscope procedures, inspection and maintenance of medical equipment, and in-hospital logistics and transportation management. Furthermore, it addresses the elderly care market by renting and selling specialized equipment and supplies, and by providing in-home nursing care services.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Goki Ishikawa
- Employees
- 5,157
- Website
- www.hugp.com
- Address
- Akasaka Intercity AIR, Tokyo, TY, 107-0052, JP
HUGroup Holdings (4544) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 2 | 5 |
| Technical Analysis | 2 | 2 | 5 |
| Moving Averages | 12 | 0 | 0 |









